Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01611155 · ClinicalTrials.gov registry record · NA
Venlafaxine in Preventing Chronic Oxaliplatin-Induced Neuropathy In Patients Receiving Combination Chemotherapy
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
NCT01611155: Completed NA study, sponsored by Mayo Clinic.
NCT01611155 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01611155, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
Study Summary
You are being asked to take part in this research study because you are going to be treated with oxaliplatin chemotherapy as part of your standard care. Oxaliplatin commonly causes neuropathy (numbing, tingling and/or pain).The purpose of this study is to compare the effects, good and/or bad, of venlafaxine with a placebo (an inactive agent) on oxaliplatin-induced neuropathy (numbing, tingling and/or pain)
Interventions
- DRUG placebo
- OTHER questionnaire administration
- OTHER quality-of-life assessment
- DRUG venlafaxine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2012-02-17 |
| Est. Completion | 2015-09-23 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01611155
The ClinicalTrials.gov registry entry for NCT01611155 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT01611155 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01611155 about?
NCT01611155 is a clinical study titled "Venlafaxine in Preventing Chronic Oxaliplatin-Induced Neuropathy In Patients Receiving Combination Chemotherapy". You are being asked to take part in this research study because you are going to be treated with oxaliplatin chemotherapy as part of your standard care. Oxaliplatin commonly causes neuropathy (numbing, tingling and/or pain).The purpose of this study is to compare the effects, good and/or bad, of ven...
What is the current status of trial NCT01611155?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2012-02-17. Estimated completion is 2015-09-23.
What interventions are being tested in trial NCT01611155?
The interventions under investigation include: placebo (DRUG), questionnaire administration (OTHER), quality-of-life assessment (OTHER), venlafaxine (DRUG).
Who is sponsoring clinical trial NCT01611155?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.